ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026
OPHN1-related neurodevelopmental disorders: clinical and genetic findings with novel variants.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pathogenic variants in the OPHN1 gene are associated with X-linked intellectual developmental disorder, Billuart type (OMIM #300486), characterized by intellectual disability, distinctive facial features, cerebellar abnormalities, ventriculomegaly, epilepsy, and variable neuropsychiatric manifestations. In this study, four male individuals from four unrelated families presenting with intellectual disability and developmental delay were evaluated. Comprehensive clinical, neuroimaging, and molecular genetic data were collected. Genetic analyses were performed using whole-exome or clinical exome sequencing. Hemizygous OPHN1 variants were identified in all individuals. Two variants, a nonsense variant, c.226del (p.Leu76Ter), and a frameshift variant, c.226_227del (p.Leu76AspfsTer2), were predicted to introduce premature termination codons resulting in loss of protein function and were classified as pathogenic or likely pathogenic. Additionally, two intronic splice-site variants (c.1527-3 C > G and c.2158 + 5G > A) were classified as variants of uncertain significance; however, in silico analyses strongly supported their potential to disrupt normal splicing. The clinical features observed in the affected individuals, including developmental delay, intellectual disability of variable severity, characteristic facial features, and cerebellar and ventricular abnormalities, were consistent with previously reported OPHN1-associated phenotypes. Neuropsychiatric features, including autism spectrum disorder and hyperactivity, were also observed, highlighting phenotypic variability. This study reports the first OPHN1-related cases from Türkiye and expands the molecular and phenotypic spectrum of OPHN1-associated neurodevelopmental disorders by identifying three novel variants. Our findings support the pathogenic relevance of both loss-of-function and splice-site variants and contribute to improved genotype-phenotype correlation and diagnostic evaluation.
Indexed as
Identifiers
42891736What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.